HYPERION THERAPEUTICS INC Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2014 12 months to Dec 31, 2014	FY2013 12 months to Dec 31, 2013	FY2012 12 months to Dec 31, 2012
Cash flows from operating activities
Net income (loss)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities
Amortization of debt discount
Depreciation
Amortization of debt discount and debt issuance costs
Re-measurement of warrants liability
Re-measurement of call option liability and preferred stock liability
Stock-based compensation expense
Amortization of debt issuance costs
Amortization of intangible asset
Impairment of goodwill (Notes 4 and 8)
Unrealized loss on foreign currency translation adjustments
Provision of inventory obsolescence
Amortization of discount on available-for-sale investments
Excess tax benefit from stock-based compensation
Changes in assets and liabilities, net of impact of acquisition of Andromeda Biotech Ltd. ("Andromeda")
Accounts receivable
Inventories
Prepaid expenses and other assets
Other non-current assets
Accounts payable
Accrued liabilities and other
Deferred revenue
Deferred rent
Net cash provided by (used in) operating activities
Cash flows from investing activities
Acquisition of property and equipment
Purchase of available-for-sale investments
Maturity of available-for-sale investments
Acquisition of Andromeda, net of cash acquired
Fair value of common stock issued in connection with the acquisition
Option to purchase BUPHENYL and AMMONUL (Note 4)
Change in restricted cash
Net cash provided by (used in) investing activities
Cash flows from financing activities
Proceeds from issuance of common stock in initial public offering, net of underwriting discounts
Proceeds from issuance of common stock in follow-on offering, net of underwriting discounts
Proceeds from issuance of common stock from stock option exercises
Proceeds from term loans
Proceeds from revolving credit line
Excess tax benefit from stock-based compensation
Proceeds from issuance of convertible notes payable
Proceeds from issuance of notes payable, net of issuance costs
Payments of offering costs
Principal payments under notes payable
Net cash provided by financing activities
Net increase in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Supplemental cash flow information
Cash paid for interest
Cash paid for income tax
Stock-based compensation capitalized into inventories
Supplemental disclosure of noncash investing and financing activities
Warrants issued in connection with notes payable
Unrealized gain (loss) on available-for-sale investments
Issuance of common stock upon automatic net exercise of warrants
Conversion of convertible notes payable and accrued interest to common stock
Conversion of Series C-1 and C-2 preferred stock to common stock
Acquisition of Andromeda (Note 4)
Cash paid for acquisition
Cash acquired in acquisition

Comments